Guest guest Posted December 13, 2006 Report Share Posted December 13, 2006 Hi Natasa, If you look at autoimmunty as a whole, then this is a 100,000 dollar question because you could drag in vaccines and other immune altering processes... but even just looking at antiviral or detoxification therapy it's a big question. With Valtrex/acyclovir (as well in this case) an adenosine pilot study that Sid Baker MD did wih the help of Dr. Jill (I have a copy of the slide in our files section and in my general presentation like at the USAAA conference which you can watch at www.recoveryvideos.com .... plug, plug, plug... as if I sold the darn thing... Here is the link to the slide. If you can't click on it, just go to the files section and look for it. http://f1.grp.yahoofs.com/v1/cBWARS-v8pHPddXe- NrGDy4eCpb4VlwgE_0owkm_VFs0KUpXe-ga5W6BhKlfRerVLGxFnuO7uWpObniaGbMWfg/ Acyclovir%20Adenosine%20Slide%20-%20Dr.%20Sid%20Baker%20 Files section http://health.groups.yahoo.com/group/mb12 valtrex/files What you'll notice is that abnormally high levels of adenosine go down and abnormally low levels go up and only one stayed the same and that one was the control. Now the thing about adenosine is that it also can block methylation if it's high or low. So that's another way it can cause autoimmunity and immune system disregulation. Now do we know for sure where adenosine should be for the individual person? No, I don't think we do, but my best guess is the center of the sine wave curve is good place to start and ultimately at our place in medical technology (really the dark ages still) the best way to tell for our children is a trial... and then to observe behavior and immune system changes, etc. For some, this is a life-changing therapy... for others not. What this study tells me is that there is an important element in play that we need to learn more about... an in the meantime a trial seems worthwhile considering it affects methylation and a good number of our kids have adenosine abnormalities. - Stan > > Hi Stan and others, wondering if this could have implications for > valtrex effects in our kids, considering that it acts on these adenosine > receptors (valtrex molecules are known to attach to these receptors and > change their function). Have a look: > > Trends Immunol. 2005 Jun;26(6):299-304. The 'danger' sensors that STOP > the immune response: the A2 adenosine receptors? > Sitkovsky MV > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itoo\ > l=pubmed_AbstractPlus & term=%22Sitkovsky+MV%22%5BAuthor%5D> ,Ohta A > <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed & cmd=Search & itoo\ > l=pubmed_AbstractPlus & term=%22Ohta+A%22%5BAuthor%5D> .New England > Inflammation and Tissue Protection Institute, Northeastern University, > Boston, MA 02115, USA. m.sitkovsky@... > Immune cells not only destroy pathogens but might also cause collateral > injuries to normal tissues. The surprisingly low incidence of > post-inflammatory complications is explained here by a 'danger-sensing' > physiological mechanism that ensures the tissue-protecting negative > feedback inhibition of overactive immune cells. We focus here on > immunoregulatory influences of 'non-immune' signaling molecules in > physiological and pathophysiological tissue microenvironments. We > propose that hypoxia-associated accumulation of extracellular adenosine > might be an important immunoregulatory signal. A2 receptors for > extracellular adenosine might act as both primary sensors of excessive > collateral tissue damage during an immune response and triggers of the > emergency downregulation of overactive immune cells. Regulation by > extracellular adenosine would protect normal organs from injury and/or > re-direct immune responses. > > PMID: 15922945 [PubMed - indexed for MEDLINE] > Natasa > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.